- Home
- SLG vs SYRE Comparison
SLG vs SYRE Comparison
Compare SLG & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLG | SYRE |
|---|---|---|
| Founded | 1980 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.6B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | SLG | SYRE |
|---|---|---|
| Price | $40.88 | $41.52 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 7 |
| Target Price | $53.84 | ★ $55.57 |
| AVG Volume (30 Days) | ★ 1.4M | 681.3K |
| Earning Date | 01-01-0001 | 05-19-2026 |
| Dividend Yield | ★ 7.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.03 | $10.91 |
| 52 Week High | $66.91 | $45.76 |
Technical Indicators
Market Signals| Indicator | SLG | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 50.57 | 60.56 |
| Support Level | $40.26 | $14.62 |
| Resistance Level | $47.34 | $45.76 |
| Average True Range (ATR) | 2.25 | 2.38 |
| MACD | 0.31 | 0.07 |
| Stochastic Oscillator | 90.00 | 61.79 |
Price Performance
Historical ComparisonAbout SLG SL Green Realty Corp
SL Green Realty is one of the largest Manhattan property owners and landlords, with interest in around 32 million square feet of wholly owned and joint-venture office space. The company has additional property exposure through its limited portfolio of well-located retail space. It operates as a real estate investment trust.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.